Nutra Pharma Corporation announced that they had signed a definitive Letter of Intent for a $4 Million financing that will fund a subsidiary joint venture. JAH Neal Holdings LLC will act as the minority Joint Venture (JV) partner with a 49% stake in the subsidiary for their $4 million investment. Nutra Pharma will maintain a 51% stake in the venture and will contribute an exclusive license for all of their Over-the-Counter (OTC) products, which currently includes: Nyloxin®, Pet Pain-Away™ and Luxury Feet. The stakeholders will jointly manage the JV. All of the parties are working diligently to complete the necessary steps to enact the creation, funding and launch of the Joint Venture subsidiary with a plan to complete the transactions by the end of the summer.